Back to top

Protagonist Therapeutics initiated with an Overweight at Barclays

Barclays analyst Etzer Darout initiated coverage of Protagonist Therapeutics (PTGX) with an Overweight rating and $72 price target Published first ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Invesco Financial Preferred ETF (PGF)

Protagonist Therapeutics, Inc. (PTGX)